A US bio-analytical firm and a prominent medical institution have finalised a research agreement to develop artificial intelligence systems for women’s healthcare. Aspira Women’s Health Inc. and Cleveland Clinic have signed a Master Collaboration and License Agreement designed to transform noninvasive diagnostics. The partnership focuses on discovering and validating novel biomarker signatures alongside creating advanced analytical models.
The joint initiative establishes a broad clinical framework across multiple areas of study. These include data generation, translational development, intellectual property collaboration and clinical research projects. By expanding access to patient samples and increasing clinical validation capabilities, the organisations aim to speed up the development and commercialisation of next-generation multiomic diagnostics.
“This collaboration marks an important inflection point for Aspira as we continue executing against our strategy to build a category defining women’s health diagnostics platform,” said Mike Buhle, Chief Executive Officer of Aspira Women’s Health. “Over the past year, we have focused on expanding our scientific capabilities, operational foundation, and long-term commercial strategy. Collaborating with Cleveland Clinic significantly enhances our ability to drive meaningful advances in women’s health diagnostics.”
The scientific program will be managed by a multidisciplinary team. Kevin Elias, M.D., from Cleveland Clinic, and Todd Pappas, Ph.D., from Aspira, will jointly lead the project. The researchers aim to merge biological data with computational technology to build highly scalable testing platforms.
“We believe the integration of multiomic biomarkers with advanced AI-driven analytics represents a highly promising frontier in precision diagnostics,” said Dr. Elias, Lilli and Seth Harris Endowed Chair for Ovarian Cancer Research at Cleveland Clinic. “We have already demonstrated the potential of this approach to improve ovarian cancer diagnostics, and we believe it can be applied more broadly across women’s health. This collaboration brings together complementary scientific, clinical, translational, and commercial expertise with the shared goal of advancing more accurate noninvasive tools that can meaningfully improve patient care and clinical decision-making.”
The business strategy aims to combine clinical insight with technological execution. Michelle Snider, SVP Product Commercialization and Innovation, stated that the deal strengthens their position where artificial intelligence, precision medicine and women’s health intersect.
“This Agreement reflects the continued evolution of Aspira’s scientific and platform strategy,” said Dr. Pappas, Chief Scientific Officer of Aspira Women’s Health. “By combining Cleveland Clinic’s translational research expertise with Aspira’s AI-enabled multiomic platform, we believe we can accelerate the development of innovative diagnostic approaches designed to improve both clinical performance and healthcare outcomes. We are building a scalable scientific framework capable of supporting multiple future applications across women’s health. The comprehensive Agreement represents a transformative advancement of Aspira’s proprietary platform technology, bringing together large-scale biomarker discovery such as proteins and microRNAs, AI-driven computational modeling, and scalable, highly specific nucleic acid detection infrastructure.”
